| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/26/2023 | 4.68% | Morgan Stanley | $44 → $37 | Maintains | Underweight |
| 08/24/2023 | 24.49% | Morgan Stanley | → $44 | Downgrades | Equal-Weight → Underweight |
| 07/28/2023 | 69.76% | JMP Securities | $65 → $60 | Maintains | Outperform |
| 07/19/2023 | 35.8% | Truist Securities | $44 → $48 | Maintains | Hold |
| 07/12/2023 | 49.95% | Jefferies | $58 → $53 | Upgrades | Hold → Buy |
| 06/08/2023 | — | Argus Research | Downgrades | Buy → Hold | |
| 05/31/2023 | 21.66% | Morgan Stanley | $59 → $43 | Maintains | Equal-Weight |
| 05/30/2023 | 24.49% | Truist Securities | $54 → $44 | Reiterates | Hold → Hold |
| 05/26/2023 | 83.9% | JMP Securities | → $65 | Reiterates | Market Outperform → Market Outperform |
| 05/24/2023 | 21.66% | JP Morgan | $56 → $43 | Downgrades | Neutral → Underweight |
| 05/23/2023 | 10.34% | Citigroup | $59 → $39 | Downgrades | Neutral → Sell |
| 05/18/2023 | 52.78% | Truist Securities | $58 → $54 | Maintains | Hold |
| 04/27/2023 | 83.9% | JMP Securities | $75 → $65 | Maintains | Outperform |
| 04/17/2023 | 75.41% | Truist Securities | $58 → $62 | Maintains | Hold |
| 02/23/2023 | 66.93% | Citigroup | $60 → $59 | Maintains | Neutral |
| 01/06/2023 | 66.93% | Morgan Stanley | $50 → $59 | Maintains | Equal-Weight |
| 12/20/2022 | 64.1% | Truist Securities | $52 → $58 | Maintains | Hold |
| 12/12/2022 | 69.76% | Citigroup | $50 → $60 | Maintains | Neutral |
| 10/27/2022 | 112.19% | JMP Securities | $85 → $75 | Maintains | Market Outperform |
| 10/27/2022 | 41.46% | Morgan Stanley | $49 → $50 | Maintains | Equal-Weight |
| 10/26/2022 | 47.12% | Truist Securities | $46 → $52 | Maintains | Hold |
| 10/17/2022 | 30.15% | Truist Securities | $60 → $46 | Maintains | Hold |
| 10/12/2022 | 35.8% | Jefferies | → $48 | Initiates Coverage On | → Hold |
| 10/11/2022 | 38.63% | Morgan Stanley | $58 → $49 | Maintains | Equal-Weight |
| 08/25/2022 | 64.1% | Morgan Stanley | $59 → $58 | Maintains | Equal-Weight |
| 07/25/2022 | 66.93% | Morgan Stanley | → $59 | Initiates Coverage On | → Equal-Weight |
| 07/20/2022 | 58.44% | Truist Securities | $70 → $56 | Maintains | Hold |
| 05/17/2022 | 89.56% | Citigroup | $70 → $67 | Maintains | Neutral |
| 01/18/2022 | 83.9% | B of A Securities | $55 → $65 | Maintains | Underperform |
| 12/17/2021 | 112.19% | JP Morgan | → $75 | Upgrades | Underweight → Neutral |
| 11/03/2021 | 146.15% | Credit Suisse | $84 → $87 | Maintains | Outperform |
| 09/15/2021 | — | BTIG | Downgrades | Buy → Neutral | |
| 02/19/2021 | 123.51% | Credit Suisse | $73 → $79 | Maintains | Outperform |
| 01/27/2021 | 126.34% | JMP Securities | $65 → $80 | Maintains | Market Outperform |
| 01/07/2021 | 106.54% | Credit Suisse | $60 → $73 | Maintains | Outperform |
| 10/29/2020 | 32.97% | Piper Sandler | $53 → $47 | Maintains | Neutral |
| 10/08/2020 | 41.46% | JP Morgan | → $50 | Downgrades | Neutral → Underweight |
| 08/12/2020 | 69.76% | Truist Securities | $55 → $60 | Maintains | Buy |
| 08/11/2020 | 49.95% | UBS | $51 → $53 | Maintains | Neutral |
| 08/11/2020 | 69.76% | Credit Suisse | $58 → $60 | Maintains | Outperform |
| 05/08/2020 | 55.61% | UBS | $65 → $55 | Maintains | Neutral |
| 05/08/2020 | 64.1% | Credit Suisse | $56 → $58 | Maintains | Outperform |
| 05/08/2020 | 83.9% | JMP Securities | $75 → $65 | Maintains | Market Outperform |
| 04/06/2020 | 30.15% | Wells Fargo | $62 → $46 | Maintains | Equal-Weight |
| 04/03/2020 | 55.61% | SunTrust Robinson Humphrey | → $55 | Initiates Coverage On | → Buy |
| 03/06/2020 | 83.9% | Credit Suisse | $70 → $65 | Maintains | Outperform |
| 02/20/2020 | 83.9% | UBS | $64 → $65 | Maintains | Neutral |
| 01/07/2020 | 64.1% | Piper Sandler | $59 → $58 | Downgrades | Overweight → Neutral |
| 12/18/2019 | 83.9% | UBS | $63 → $65 | Maintains | Neutral |
| 10/08/2019 | 83.9% | Wells Fargo | $68 → $65 | Maintains | Market Perform |
| 01/03/2019 | 58.44% | SunTrust Robinson Humphrey | → $56 | Initiates Coverage On | → Buy |
| 12/18/2018 | 61.27% | Credit Suisse | → $57 | Initiates Coverage On | → Outperform |
| 12/12/2018 | 61.27% | Credit Suisse | → $57 | Initiates Coverage On | → Outperform |
| 11/28/2018 | 64.1% | UBS | → $58 | Initiates Coverage On | → Neutral |
| 11/02/2018 | 69.76% | Citigroup | $66 → $60 | Maintains | Neutral |
| 11/02/2018 | 75.41% | JMP Securities | $66 → $62 | Maintains | Market Outperform |
| 11/01/2018 | 55.61% | Wells Fargo | $61 → $55 | Maintains | Market Perform |
| 11/01/2018 | 52.78% | Cantor Fitzgerald | $59 → $54 | Maintains | Neutral |
What is the target price for Integra Lifesciences (IART)?
The latest price target for Integra Lifesciences (NASDAQ: IART) was reported by Morgan Stanley on October 26, 2023. The analyst firm set a price target for $37.00 expecting IART to rise to within 12 months (a possible 4.68% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Integra Lifesciences (IART)?
The latest analyst rating for Integra Lifesciences (NASDAQ: IART) was provided by Morgan Stanley, and Integra Lifesciences maintained their underweight rating.
When is the next analyst rating going to be posted or updated for Integra Lifesciences (IART)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Integra Lifesciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Integra Lifesciences was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.
Is the Analyst Rating Integra Lifesciences (IART) correct?
While ratings are subjective and will change, the latest Integra Lifesciences (IART) rating was a maintained with a price target of $44.00 to $37.00. The current price Integra Lifesciences (IART) is trading at is $35.35, which is out of the analyst's predicted range.